The DTNBP1 Knockout NCI-H1975 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal population derived from the NCI-H1975 human lung adenocarcinoma cell line, with targeted disruption of the DTNBP1 gene. This polyclonal pool enables robust loss-of-function analyses of dysbindin, the encoded BLOC-1 subunit, in a genetic background harboring endogenous EGFR T790M and L858R mutations. The pooled format avoids clonal selection bias while providing a versatile tool for population-level studies of gene function.
NCI-H1975 is a well-characterized model of non-small cell lung adenocarcinoma, originally isolated from a female patient, and exhibits adherent epithelial morphology. The activating EGFR T790M and L858R mutations drive constitutive kinase activity, making these cells a standard system for investigating EGFR signaling, primary resistance to first-generation tyrosine kinase inhibitors (TKIs), and acquired resistance mechanisms. The line??s molecular definition supports reproducible experimental contexts for drug response and signaling studies.
DTNBP1 encodes dysbindin, a core component of the BLOC-1 complex that coordinates lysosome-related organelle biogenesis through interactions with BLOC1S1, BLOC1S2, SNAPIN, and AP-3 complex subunits. Upstream, DTNBP1 expression is influenced by EGFR pathway activity, hypoxia, and the transcription factor SOX2. Downstream, dysbindin modulates PI3K/AKT/mTOR signaling, SNARE-mediated vesicle fusion, and glutamatergic transmission, ultimately affecting cell cycle progression via Cyclin D1. This network positions dysbindin at the intersection of membrane trafficking and oncogenic signaling.
In the context of NCI-H1975, DTNBP1 knockout likely compromises BLOC-1 complex assembly, impairing lysosomal trafficking and autophagy flux while perturbing EGFR-driven signaling cascades. Disruption of the AKT/mTOR axis downstream of dysbindin may alter cell proliferation, survival, and sensitivity to EGFR inhibitors such as erlotinib. Thus, this knockout model serves as a unique platform to dissect how dysbindin contributes to TKI resistance and tumor cell adaptation in EGFR-mutant lung adenocarcinoma.
These polyclonal knockout cells are suited for applications in lung cancer biology, EGFR-TKI resistance, autophagy regulation, and drug target validation. Researchers can employ western blotting and RT-qPCR for expression profiling, cell proliferation and migration assays, erlotinib dose-response studies, autophagy flux measurements, and immunofluorescence. For technical inquiries or further assistance, please contact Ascent Research.
